Recent data have led to the approval of three PD-1/PD-L1 inhibitors, including nivolumab, pembrolizumab, and atezolizumab, for the treatment of advanced NSCLC after first-line therapy [3–7]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.